Dual therapy containing vonoprazan and amoxicillin had showed excellent eradication results
with Helicobacter pylori first-line treatment. However, no study has examined its efficacy
for H. pylori rescue treatment. Rifabutin has low antibiotic resistance, superior
antibacterial activity in vitro, and stability in the gastric acid environment. Several
studies have confirmed the efficacy of rifabutin-containing triple therapy as a first-line or
rescue treatment for H. pylori. The purpose of this study was to evaluate the efficacy and
safety of dual therapy vesus rifabutin-containing triple therapy versus classical
bismuth-containing quadruple therapy as rescue therapy for the eradication of refractory
Helicobacter pylori.